Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, Fallet V, Khoudour N, Guidi M, Vidal M, Declèves X, Csajka C, Alexandre J, Cadranel J, Fabre E, Wislez M, Goldwasser F, Blanchet B. Rodier T, et al. Among authors: fabre e. Pharmaceutics. 2022 Sep 1;14(9):1844. doi: 10.3390/pharmaceutics14091844. Pharmaceutics. 2022. PMID: 36145591 Free PMC article.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Among authors: fabre e. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso, Guidi M, Khoudour N, Pascaline Boudou-Rouquette, Fabre E, Tlemsani C, Arrondeau J, François Goldwasser, Vidal M, Schneider MP, Wagner AD, Widmer N, Blanchet B, Csajka C. Evelina Cardoso, et al. Among authors: fabre e. Clin Ther. 2020 Jul;42(7):1302-1316. doi: 10.1016/j.clinthera.2020.05.008. Epub 2020 Jul 4. Clin Ther. 2020. PMID: 32631634
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy.
Chelabi S, Mignard X, Leroy K, Monnet I, Brosseau S, Theou-Anton N, Massiani MA, Friard S, Duchemann B, Fabre E, Giroux-Leprieur E, Cadranel J, Wislez M. Chelabi S, et al. Among authors: fabre e. Cancers (Basel). 2021 Oct 13;13(20):5132. doi: 10.3390/cancers13205132. Cancers (Basel). 2021. PMID: 34680280 Free PMC article.
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F. Boudou-Rouquette P, et al. Among authors: fabre e. EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20. EBioMedicine. 2021. PMID: 34688030 Free PMC article.
Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.
Pourmir I, Elaidi R, Maaradji Z, De Saint Basile H, Ung M, Ismaili M, Fournier L, Rance B, Gibault L, Ben Dhiab R, Gazeau B, Fabre E. Pourmir I, et al. Among authors: fabre e. Cancers (Basel). 2023 Nov 26;15(23):5587. doi: 10.3390/cancers15235587. Cancers (Basel). 2023. PMID: 38067291 Free PMC article.
237 results